jeremy, Author at FACIT

FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma

Posted on December 8, 2020 (October 4, 2022)

December 8, 2020 – December 8, 2020 – FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.

FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster

Posted on December 1, 2020 (October 4, 2022)

December 1, 2020 – December 1, 2020 – FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.

FACIT Features: Portfolio company KA Imaging secures FDA approval for portable dual-energy x-ray detector

Posted on September 17, 2020 (October 4, 2022)

September 17, 2020 – September 17, 2020 – Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.

FACIT congratulates Fusion Pharma on its Initial Public Offering

Posted on June 26, 2020 (September 16, 2024)

June 26, 2020 – June 26, 2020 – FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.

FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund

Posted on June 23, 2020 (April 9, 2024)

June 23, 2020 – June 23, 2020 – FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.

FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)

Posted on June 9, 2020 (July 4, 2024)

June 9, 2020 – June 9, 2020 – FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).

FACIT Features: OICR leads international team to generate world’s most comprehensive cancer genome map

Posted on February 6, 2020 (October 4, 2022)

February 6, 2020 – February 6, 2020 – The output from this global study vastly improves the fundamental understanding of cancer and will provide guidance and new directions for its diagnosis and treatment

FACIT Announces Artificial Intelligence pitch as Winner of 2020 Falcons’ Fortunes on World Cancer Day

Posted on February 5, 2020 (July 4, 2024)

February 5, 2020 – February 5, 2020 – The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency, consistency and quality of delivering cancer care.

FACIT in the News – @globeandmail

Posted on February 4, 2020 (December 6, 2021)

February 4, 2020 – “Commercializing innovation for cancer patients and economic impact”, February 4, 2020

FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund

Posted on January 28, 2020 (July 4, 2024)

January 28, 2020 – January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.

Author: jeremy

Posts by jeremy